Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial
Evan S Dellon, Ikuo Hirano, Chinyu Su(Pfizer (United States)), Fabio Cataldi(Pfizer (United States)), Thai Nguyen-Cleary(Pfizer (United States)), Margaret H. Collins(Cincinnati Children's Hospital Medical Center), Huaming Tan(Pfizer (United States)), Pamela Clax(Pfizer (United States)), John Woolcott(Pfizer (United States)), Márjori Dulcine, Jin Yu, Albert J Bredenoord, Wenjin Wang, Luc Biedermann, Joseph T. Wu(Cardiovascular Institute of the South), Hamish Philpott(The University of Adelaide)
Cited by 0
Related Papers
Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study
|The Lancet|2020|4.9k
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k
Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference
|Gastroenterology|2018|1.1k
Hand, foot, and mouth disease in China, 2008–12: an epidemiological study
|The Lancet Infectious Diseases|2014|965
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
|New England Journal of Medicine|2022|452